Fehr Martin, Cathomas Gieri, Graber Anne, Makert Eva, Gaus Elisabeth, Boggian Katia
Department for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, Switzerland.
Institute of Pathology, Cantonal Hospital Basel-Land, Liestal, Switzerland.
Med Mycol Case Rep. 2019 Dec 3;27:14-16. doi: 10.1016/j.mmcr.2019.12.005. eCollection 2020 Mar.
We report the case of a 71 years old patient with chronic lymphocytic leukemia (CLL), who developed a rapidly progressing multi-fungal infection including mucormycosis of the central nervous system (CNS) during treatment with ibrutinib. On autopsy mucorales species were demonstrated intravascularly by histomorphology of several organs and lymph nodes and were characterized as by polymerase-chain reaction (PCR) - analysis. In addition, invasive pulmonary was found and also confirmed by PCR. To the best of our knowledge, this is the first confirmation of a multi-fungal sepsis and invasive CNS-infection with mucorales species under ibrutinib. Knowing the risk for invasive fungal disease in patients under ibrutinib, identifying the pathogen and early initiation of specific treatment is crucial for a good clinical outcome especially in mucormycosis.
我们报告了一例71岁的慢性淋巴细胞白血病(CLL)患者,该患者在接受依鲁替尼治疗期间发生了快速进展的多真菌感染,包括中枢神经系统(CNS)毛霉菌病。尸检时,通过多个器官和淋巴结的组织形态学在血管内发现了毛霉目真菌,并通过聚合酶链反应(PCR)分析进行了鉴定。此外,还发现了侵袭性肺感染,同样通过PCR得到证实。据我们所知,这是依鲁替尼治疗下首次确认的多真菌败血症和侵袭性中枢神经系统毛霉目真菌感染。了解依鲁替尼治疗患者发生侵袭性真菌病的风险、识别病原体并尽早开始特异性治疗对于获得良好的临床结局至关重要,尤其是在毛霉菌病方面。